Tumor News and Research

RSS

Increasing age associated with higher risk of death from breast cancer

Among postmenopausal women with hormone receptor-positive breast cancer, increasing age was associated with a higher risk of death from breast cancer, according to a study in the February 8 issue of JAMA.

8 Feb 2012

Clinical Cancer Research publishes results of Aduro's ANZ-100 and CRS-207 Phase 1 studies

Aduro BioTech, Inc. is pleased to announce the publication of two therapeutic cancer vaccine Phase 1 studies in Clinical Cancer Research. In the article, which was featured as one of the highlights of the issue, Dr. Dung Le et al. reported that intravenous administration of ANZ-100 and CRS-207 was well tolerated in subjects with advanced, treatment-refractory cancers.

7 Feb 2012

Three new targeted drugs can lead to fatal cancer complications

Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that the risk remains low, but should be taken into account by physicians and patients.

7 Feb 2012

Cyclin D1 oncogene may promote chromosomal instability

A team of researchers at Jefferson's Kimmel Cancer Center (KCC) led by Richard G. Pestell, M.D., PhD., FACP, Director of the KCC and Chair of the Department of Cancer Biology, have shown in a study published online Feb. 6 in the Journal of Clinical Investigation that the oncogene cyclin D1 may promote a genetic breakdown known as chromosomal instability (CIN). CIN is a known, yet poorly understood culprit in tumor progression.

7 Feb 2012

Inhibiting MET signaling in glioblastoma has major therapeutic value

A recent discovery by Van Andel Research Institute (VARI) scientists enables the prediction of patient sensitivity to proposed drug therapies for glioblastoma - the most common and most aggressive malignant brain tumor in humans.

7 Feb 2012

Researchers reveal how molecular imaging can solve breast cancer mysteries

In two new studies featured in the February issue of the Journal of Nuclear Medicine, researchers are revealing how molecular imaging can be used to solve mysteries about difficult cases of breast cancer.

7 Feb 2012

Successful six organ transplants in 9 year old

A 9 year old girl from Maine is making recovery days after surgeons transplanted six of her organs in a groundbreaking medical procedure.

6 Feb 2012

ABC2, Exosome collaborate to explore RNA biofluid-based diagnostic technology in brain cancer

Accelerate Brain Cancer Cure and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer.

6 Feb 2012

Russian neurosurgical institute acquires Leksell Gamma Knife Perfexion system

Russia's first Leksell Gamma Knife Perfexion system has found a home at the renowned N.N. Burdenko Neurosurgical Institute, just a five-minute car ride from Moscow's Red Square.

From Elekta 6 Feb 2012

Pyromaker can more accurately identify complex genetic mutations

DNA sequencing to detect genetic mutations can aid in the diagnosis and selection of treatment for cancer. Current methods of testing DNA samples, Sanger sequencing and pyrosequencing, occasionally produce complex results that can be difficult or impossible to interpret. Scientists at the Johns Hopkins University School of Medicine have developed a free software program, Pyromaker, that can more accurately identify such complex genetic mutations.

6 Feb 2012

Combination of Toca 511 and 5-FC may prolong survival in glioblastoma

Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and provides a dramatic survival benefit in mouse models of glioblastoma.

4 Feb 2012

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012

UCSD Moores Cancer Center offers NovoTTF procedure for patients with GBM

Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM). In the United States, each year, approximately 10,000 patients are affected by GBM. Now, a novel investigational device - available only at clinical trial sites - is offering new hope to these patients.

4 Feb 2012

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Exelixis, Inc. today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of cabozantinib.

3 Feb 2012

Urine-based biomarkers may lead to development of test for high-risk prostate cancer

Initial results of a multicenter study coordinated by researchers at Fred Hutchinson Cancer Research Center indicates that two investigational urine-based biomarkers are associated with prostate cancers that are likely to be aggressive and potentially life-threatening among men who take a "watchful waiting," or active-surveillance approach to manage their disease.

3 Feb 2012

Scientists identify molecular switch that controls ATF2's dual functions

The National Cancer Institute (NCI) estimates that as many as one in 51 men and women will be diagnosed with melanoma-the deadliest form of skin cancer-at some point during their lifetimes. A research team led by Ze'ev Ronai, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) is working to unravel the molecular mechanisms underlying the development and progression of this disease in hopes of improving prevention and treatment strategies

3 Feb 2012

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

3 Feb 2012

Molecular subtypes of lung cancer manifest as different diseases

Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the body.

3 Feb 2012

Gene activity may help explain how vigorous exercise improves survival from prostate cancer

Scientists at the University of California, San Francisco (UCSF) have identified nearly 200 genes in the healthy prostate tissue of men with low-grade prostate cancer that may help explain how physical activity improves survival from the disease.

2 Feb 2012

Cancer Genomics now available online

Genome Research publishes online and in print today a special issue entitled, "Cancer Genomics," highlighting insights gained form cutting-edge genomic and epigenomic analyses of cancer.

2 Feb 2012